Title: |
Chinese guidelines for evidence-based evaluation of off-label drug use in ophthalmology |
Edition: |
Original |
Classification: |
Standard guideline |
Field: |
Treatment |
Countries and regions: |
China |
Guidelines users: |
|
Evidence classification method: |
Grading of Recommendations, Assessment, Development and Evaluations, GRADE |
Development unit: |
the Hospital Pharmacy Professional Committee, Chinese Pharmaceutical Association; Beijing Tongren Hospital, Capital Medical University |
Registration time: |
2021-04-19 |
Registration number: |
IPGRP-2021CN096 |
Purpose of the guideline: |
Off-label drug use in ophthalmology is widespread in different medical institutions in China. However, there are only scattered studies evaluating its effectiveness and safety, and no unified conclusion has been reached yet. We plan to systematically evaluate the rationality of current off-label drug use in domestic medical institutions in order to develop evidence-based evaluation guidelines for off-label drug use in ophthalmology in China, so as to provide evidence support for rational drug use in ophthalmology and promote safe and correct drug use. |